RxDoctor Payments Data

Sreedevi Chittineni, MD

Nephrology · Evergreen Park, ILNPI 1871532796

Payments from drug & device makers

$7,574in general payments, 2019–2025

Across 18 payments — averaging $420.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scpharmaceuticals Inc.$7K
  • Radiometer America, Inc$280
  • Vifor Pharma, Inc.$200
  • Travere Therapeutics, Inc.$106
  • AstraZeneca$99
  • Fresenius USA Marketing, Inc.$93
  • plus $162 from 3 others
$1,125in research payments, 2019–2025

Across 1 payment — averaging $1125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$1K

What the payments were for

  • Consulting fees$3705%
  • Speaking & faculty fees$6,20082%
  • Travel & lodging$5437%
  • Food & beverage$3615%
  • Education$991%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,574 in reported general payments places this provider in the 80th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$180,849
Medicare patients
179
Services billed
1,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide54$157,168
AuryxiaFerric Citrate24$46,195
Lanthanum Carbonate11$9,427
Sevelamer Carbonate88$8,156
Calcium Acetate14$1,697
Hydralazine Hcl16$194
Carvedilol21$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$93$157,16854 claims
Akebia Therapeutics IncAuryxia$60$46,19524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 524 nephrology providers in Illinois.

Other nephrology in Evergreen Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →